Literature DB >> 26446865

The effects of a single intravenous injection of novel activin A/BMP-2 (AB204) on toxicity and the respiratory and central nervous systems.

Byung-Hak Yoon1,2, Jae Hyup Lee3, Kyuheum Na4, Chihoon Ahn1, Jongho Cho4, Hyun Chan Ahn4, Jungyoun Choi1, Hyosun Oh1, Byong Moon Kim4, Senyon Choe1,5.   

Abstract

The purpose of this study was to determine the effects of a single intravenous injection of a novel osteoinductive material, activin A/BMP-2 (AB204), to rodents on toxicity and their respiratory functions and central nervous system (CNS). A single intravenous injection of AB204 was given to Sprague-Dawley (SD) rats in doses of 0, 0.625, 2.5 and 10 mg/kg to observe the mortality rate, the general symptoms for 14 days. The experimental groups were also given 0.2, 0.4 and 0.8 mg/kg of AB204, respectively, and the respiration rate, the tidal volume and the minute volume were measured for 240 min. The experimental groups of imprinting control region (ICR) mice were given a single intravenous injection of 0.2, 0.4 and 0.8 mg/kg of AB204, respectively. Their body temperature was taken and general behaviors were observed to evaluate the effect of AB204 on the CNS for 240 min. The study on toxicity of a single intravenous injection found no death or abnormal symptoms, abnormal findings from autopsy, or abnormal body weight gain or loss in all the experimental groups. No abnormal variation associated with the test substance was observed in the respiration rate, the tidal volume, the minute volume, body temperature or the general behaviors. On the basis of these results, the approximate lethal dose of AB204 for a single intravenous injection exceeds 10 mg/kg for SD rats and a single intravenous injection of ≤0.8 mg/kg AB204 has no effect on their respiratory system for SD rat and no effect on their CNS for ICR mice.

Entities:  

Keywords:  Activin A; BMP-2; central nervous system; respiratory function; toxicity

Mesh:

Substances:

Year:  2015        PMID: 26446865      PMCID: PMC5922772          DOI: 10.3109/01480545.2015.1092548

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  20 in total

1.  Identification of a binding site on the type II activin receptor for activin and inhibin.

Authors:  P C Gray; J Greenwald; A L Blount; K S Kunitake; C J Donaldson; S Choe; W Vale
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

Review 2.  Bone morphogenetic proteins and spinal surgery.

Authors:  Harvinder S Sandhu
Journal:  Spine (Phila Pa 1976)       Date:  2003-08-01       Impact factor: 3.468

3.  Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine.

Authors:  Joseph D Smucker; John M Rhee; Kern Singh; S Tim Yoon; John G Heller
Journal:  Spine (Phila Pa 1976)       Date:  2006-11-15       Impact factor: 3.468

4.  Smad8 mediates the signaling of the ALK-2 [corrected] receptor serine kinase.

Authors:  Y Chen; A Bhushan; W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 5.  A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.

Authors:  Eugene J Carragee; Eric L Hurwitz; Bradley K Weiner
Journal:  Spine J       Date:  2011-06       Impact factor: 4.166

6.  Osteolysis in transforaminal lumbar interbody fusion with bone morphogenetic protein-2.

Authors:  Jeffrey B Knox; Joseph M Dai; Joseph Orchowski
Journal:  Spine (Phila Pa 1976)       Date:  2011-04-15       Impact factor: 3.468

7.  Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data.

Authors:  Mark C Simmonds; Jennifer V E Brown; Morag K Heirs; Julian P T Higgins; Richard J Mannion; Mark A Rodgers; Lesley A Stewart
Journal:  Ann Intern Med       Date:  2013-06-18       Impact factor: 25.391

Review 8.  Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis.

Authors:  Rongwei Fu; Shelley Selph; Marian McDonagh; Kimberly Peterson; Arpita Tiwari; Roger Chou; Mark Helfand
Journal:  Ann Intern Med       Date:  2013-06-18       Impact factor: 25.391

9.  Designer TGFβ superfamily ligands with diversified functionality.

Authors:  George P Allendorph; Jessica D Read; Yasuhiko Kawakami; Jonathan A Kelber; Michael J Isaacs; Senyon Choe
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

10.  Acute Intravenous Injection Toxicity Study of Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 in Rat.

Authors:  Jae Hyup Lee; Eui-Nam Lee; Bong-Soon Chang; Choon-Ki Lee
Journal:  Asian Spine J       Date:  2014-04-08
View more
  2 in total

Review 1.  Bone Morphogenetic Protein-Based Therapeutic Approaches.

Authors:  Jonathan W Lowery; Vicki Rosen
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 2.  A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives.

Authors:  Jonathan W Lowery; Brice Brookshire; Vicki Rosen
Journal:  Stem Cells Int       Date:  2016-06-28       Impact factor: 5.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.